INTERNATIONAL JOURNAL OF HEMATOLOGY

Scope & Guideline

Navigating the Future of Blood Health Research

Introduction

Welcome to the INTERNATIONAL JOURNAL OF HEMATOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of INTERNATIONAL JOURNAL OF HEMATOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0925-5710
PublisherSPRINGER JAPAN KK
Support Open AccessNo
CountryJapan
TypeJournal
Convergefrom 1991 to 2024
AbbreviationINT J HEMATOL / Int. J. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO 105-6005, JAPAN

Aims and Scopes

The International Journal of Hematology focuses on advancing the field of hematology through rigorous research and clinical studies. The journal encompasses a wide array of topics related to blood disorders, treatments, and innovative methodologies that enhance our understanding of hematological conditions.
  1. Hematological Malignancies:
    The journal extensively covers research on hematological malignancies such as leukemia, lymphoma, and myeloma, focusing on their pathophysiology, diagnosis, and treatment strategies.
  2. Bone Marrow and Stem Cell Transplantation:
    A significant portion of the research is dedicated to the methodologies and outcomes of bone marrow and stem cell transplantation, including allogeneic and autologous transplants.
  3. Coagulation Disorders:
    The journal addresses various coagulation disorders, including hemophilia and thrombocytopenia, examining both the clinical implications and therapeutic approaches.
  4. Transfusion Medicine:
    Research related to blood transfusion practices, including safety and efficacy, is a core area of focus, highlighting advancements in transfusion strategies.
  5. Genetic and Molecular Pathology:
    There is a significant emphasis on the genetic and molecular aspects of hematological diseases, including studies on mutations, gene expression, and their implications for treatment.
  6. Innovative Therapies and Clinical Trials:
    The journal highlights the latest innovations in therapy, including novel drug therapies, immunotherapies, and clinical trial outcomes that impact patient care.
  7. Patient Outcomes and Quality of Life:
    Research evaluating patient outcomes, quality of life, and psychosocial aspects of living with hematological disorders is increasingly featured, emphasizing holistic care.
The International Journal of Hematology has identified several trending and emerging themes that reflect the current advancements and interests in the field of hematology. These trends highlight the evolving nature of research priorities and the integration of innovative approaches to treatment.
  1. Precision Medicine:
    There is a marked increase in research focusing on precision medicine approaches in hematology, tailoring treatments based on genetic and molecular profiling of patients.
  2. Immunotherapy Developments:
    Studies on immunotherapy, particularly CAR-T cell therapies and bispecific antibodies, are trending, reflecting a significant shift towards utilizing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Outcomes Research:
    Research that provides real-world evidence on treatment effectiveness and patient outcomes is gaining traction, emphasizing the need for practical insights beyond clinical trial settings.
  4. Molecular and Genetic Insights:
    Emerging themes include detailed molecular and genetic analyses of hematological disorders, contributing to better understanding of disease mechanisms and targeted therapies.
  5. Management of COVID-19 in Hematology Patients:
    Given the global pandemic, there is a growing interest in understanding the implications of COVID-19 on patients with hematological conditions, including treatment adaptations and outcomes.
  6. Patient-Centric Care and Quality of Life:
    Research focusing on patient-reported outcomes and quality of life measures is increasingly emphasized, reflecting a broader understanding of patient experiences and needs.

Declining or Waning

While the International Journal of Hematology has a robust focus on several key areas, some themes have shown a decline in prominence over recent years. This can indicate shifts in research interest or advancements in treatment that may render previous topics less critical.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in publications focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and personalized medicine.
  2. Basic Hematology Research:
    Basic research in hematology, particularly studies that do not translate into clinical applications, appears to be waning as the emphasis moves towards translational and clinical research.
  3. Longitudinal Studies of Established Treatments:
    Longitudinal studies examining established treatment regimens without new intervention strategies have become less frequent, possibly due to a focus on novel therapies.
  4. Epidemiological Studies:
    The publication of epidemiological studies related to hematological conditions has declined, potentially reflecting a shift towards more clinical and therapeutic research.
  5. Animal Models in Hematology Research:
    Research utilizing animal models for hematological studies is less frequently published, as there is a growing preference for human-centric clinical research.

Similar Journals

Hematology

Connecting Minds: Advancing the Science of Hematology Together
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

CANCER JOURNAL

Exploring New Frontiers in Cancer Mechanisms and Therapies.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

ANNALS OF HEMATOLOGY

Empowering the scientific community with quality contributions.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

BONE MARROW TRANSPLANTATION

Elevating Standards in Hematology and Transplantation.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

Blood Cancer Journal

Empowering discovery through open-access scholarship.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

ACTA HAEMATOLOGICA

Connecting Experts in Hematology for Global Impact
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

Therapeutic Advances in Hematology

Empowering hematology professionals with cutting-edge findings.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Hematologie

Fostering Knowledge in Blood Health
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

Hematology-American Society of Hematology Education Program

Advancing Hematology through Expert Education
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

CURRENT OPINION IN HEMATOLOGY

Empowering clinicians and researchers with cutting-edge insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.